Arsanis, a biosciences company, has started the first cohort in its Phase one clinical trial of ASN100, it was reported yesterday.

The product is a novel combination of two monoclonal antibodies that target the pathogen Staphylococcus aureus. It was discovered in partnerships with Arsanis' strategic partner, Adimab LLC (Lebanon, NH, US), using its antibody discovery platform. The programme has been supported by the Austrian Research Promotion Agency from conception to clinical testing.

The company is conducting the study in Vienna, Austria, and will examine the safety, tolerability, and pharmacokinetics of ASN100 in healthy volunteers.